Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.
Santini D, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, Ceruso MS, Barni S, Bertocchi P, Marinelli S, Marchetti P, Russo A, Scartozzi M, Faloppi L, Santoni M, Cascinu S, Maiello E, Silvestris F, Tucci M, Ibrahim T, Masi G, Gnoni A, Comandone A, Fazio N, Conti A, Imarisio I, Pisconti S, Giommoni E, Cinieri S, Catalano V, Palmieri VO, Infante G, Aieta M, Trogu A, Gadaleta CD, Brunetti AE, Lorusso V, Silvestris N. Santini D, et al. Among authors: aieta m. PLoS One. 2014 Aug 29;9(8):e105268. doi: 10.1371/journal.pone.0105268. eCollection 2014. PLoS One. 2014. PMID: 25170882 Free PMC article.
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
International Prognostic Factors Study Group; Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. International Prognostic Factors Study Group, et al. J Clin Oncol. 2010 Nov 20;28(33):4906-11. doi: 10.1200/JCO.2009.26.8128. Epub 2010 Oct 18. J Clin Oncol. 2010. PMID: 20956623
Carcinogenesis of pancreatic adenocarcinoma: precursor lesions.
Gnoni A, Licchetta A, Scarpa A, Azzariti A, Brunetti AE, Simone G, Nardulli P, Santini D, Aieta M, Delcuratolo S, Silvestris N. Gnoni A, et al. Among authors: aieta m. Int J Mol Sci. 2013 Sep 30;14(10):19731-62. doi: 10.3390/ijms141019731. Int J Mol Sci. 2013. PMID: 24084722 Free PMC article. Review.
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry.
Pedrazzoli P, Martinelli G, Gianni AM, Da Prada GA, Ballestrero A, Rosti G, Frassineti GL, Aieta M, Secondino S, Cinieri S, Fedele R, Bengala C, Bregni M, Grasso D, De Giorgi U, Lanza F, Castagna L, Bruno B, Martino M; of Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule staminali emopoietiche e terapia cellulare (GITMO) – Sezione Tumori Solidi. Pedrazzoli P, et al. Among authors: aieta m. Biol Blood Marrow Transplant. 2014 Apr;20(4):501-6. doi: 10.1016/j.bbmt.2013.12.569. Epub 2013 Dec 27. Biol Blood Marrow Transplant. 2014. PMID: 24374214 Free article.
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, Grossi F, De Pas T, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsypin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H. Gregorc V, et al. Among authors: aieta m. Lancet Oncol. 2014 Jun;15(7):713-21. doi: 10.1016/S1470-2045(14)70162-7. Epub 2014 May 13. Lancet Oncol. 2014. PMID: 24831979 Free article. Clinical Trial.
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Antonuzzo L, et al. Among authors: aieta m. World J Gastroenterol. 2015 Jun 21;21(23):7281-8. doi: 10.3748/wjg.v21.i23.7281. World J Gastroenterol. 2015. PMID: 26109816 Free PMC article. Clinical Trial.
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, Nappi A, Bordonaro AR, Rachiglio M, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E; CAPRI-GOIM investigators. Ciardiello F, et al. Ann Oncol. 2016 Jun;27(6):1055-1061. doi: 10.1093/annonc/mdw136. Epub 2016 Mar 21. Ann Oncol. 2016. PMID: 27002107 Free article. Clinical Trial.
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Lolli C, Basso U, Derosa L, Scarpi E, Sava T, Santoni M, Crabb SJ, Massari F, Aieta M, Conteduca V, Maruzzo M, La Russa F, Wheater M, Berardi R, Galli L, De Giorgi U. Lolli C, et al. Among authors: aieta m. Oncotarget. 2016 Aug 23;7(34):54564-54571. doi: 10.18632/oncotarget.10515. Oncotarget. 2016. PMID: 27409344 Free PMC article.
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.
Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli V, Nasti G, Nappi A, Botti G, Tatangelo F, Chicchinelli N, Montrone M, Sebastio A, Guarino T, Simone G, Graziano P, Chiarazzo C, Maggio G, Longhitano L, Manusia M, Cartenì G, Nappi O, Micheli P, Leo L, Rossi S, Cassano A, Tommaselli E, Giordano G, Sponziello F, Marino A, Rinaldi A, Romito S, Muda AO, Lorusso V, Leo S, Barni S, Grimaldi G, Aieta M. Martinelli E, et al. Among authors: aieta m. ESMO Open. 2017 Feb 20;1(6):e000086. doi: 10.1136/esmoopen-2016-000086. eCollection 2016. ESMO Open. 2017. PMID: 28848656 Free PMC article.
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. De Placido S, et al. Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Lancet Oncol. 2018. PMID: 29482983 Clinical Trial.
129 results